Technical Analysis for GANX - Gain Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 4.36 | 1.63% | 0.07 |
GANX closed up 1.63 percent on Monday, March 18, 2024, on 41 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.63% | |
Bollinger Band Squeeze | Range Contraction | 1.63% | |
Stochastic Reached Oversold | Weakness | 1.63% | |
BB Squeeze + Lower Band Touch | Range Contraction | 1.63% | |
Inside Day | Range Contraction | 1.63% |
Alert | Time |
---|---|
Lower Bollinger Band Support | about 11 hours ago |
60 Minute Opening Range Breakdown | about 12 hours ago |
60 Minute Opening Range Breakout | about 13 hours ago |
Non-ADX 1,2,3,4 Pullback Entry | about 13 hours ago |
Rose Above Previous Day's High | about 13 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.19 |
52 Week Low | 2.0 |
Average Volume | 172,979 |
200-Day Moving Average | 3.68 |
50-Day Moving Average | 4.20 |
20-Day Moving Average | 4.55 |
10-Day Moving Average | 4.54 |
Average True Range | 0.30 |
RSI (14) | 47.37 |
ADX | 19.04 |
+DI | 19.39 |
-DI | 22.58 |
Chandelier Exit (Long, 3 ATRs) | 4.28 |
Chandelier Exit (Short, 3 ATRs) | 5.00 |
Upper Bollinger Bands | 4.82 |
Lower Bollinger Band | 4.27 |
Percent B (%b) | 0.16 |
BandWidth | 12.02 |
MACD Line | 0.05 |
MACD Signal Line | 0.12 |
MACD Histogram | -0.0748 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.74 | ||||
Resistance 3 (R3) | 4.74 | 4.62 | 4.67 | ||
Resistance 2 (R2) | 4.62 | 4.52 | 4.62 | 4.65 | |
Resistance 1 (R1) | 4.49 | 4.47 | 4.56 | 4.49 | 4.63 |
Pivot Point | 4.37 | 4.37 | 4.40 | 4.37 | 4.37 |
Support 1 (S1) | 4.24 | 4.27 | 4.31 | 4.24 | 4.09 |
Support 2 (S2) | 4.12 | 4.22 | 4.12 | 4.07 | |
Support 3 (S3) | 3.99 | 4.12 | 4.05 | ||
Support 4 (S4) | 3.99 |